4/3/2025

Nelarabine Injection

Products Affected - Description

- Nelarabine injection, Sagent, 5 mg/mL, 50 mL vial, 1 count, NDC 25021-0259-50
- Nelarabine injection, Sagent, 5 mg/mL, 50 mL vial, 6 count, NDC 25021-0259-51
- Nelarabine injection, Zydus, 5 mg/mL, 50 mL vial, 1 count, NDC 70710-1726-01
- Nelarabine injection, Zydus, 5 mg/mL, 50 mL vial, 6 count, NDC 70710-1726-08

Reason for the Shortage

- Alembic has nelarabine injection available.
- Amneal has nelarabine injection available.
- Dr. Reddy's has nelarabine injection available.
- Meitheal has nelarabine injection available.
- Novadoz is shipping to forecast.
- Sagent did not provide a reason for the shortage.
- Sandoz has Arranon injection available.
- Shorla Oncology has nelarabine injection available.
- X-Gen has nelarabine injection available.
- Zydus states the reason for the shortage is regulatory delay.

Available Products

- Arranon injection, Sandoz, 5 mg/mL, 50 mL vial, 1 count, NDC 00078-0683-61
- Nelarabine injection, Alembic, 5 mg/mL, 50 mL vial, 1 count, NDC 62232-0813-50
- Nelarabine injection, Alembic, 5 mg/mL, 50 mL vial, 6 count, NDC 62232-0813-63
- Nelarabine injection, Amneal, 5 mg/mL, 50 mL vial, 1 count, NDC 70121-1743-01
- Nelarabine injection, Amneal, 5 mg/mL, 50 mL vial, 6 count, NDC 70121-1743-04
- Nelarabine injection, Dr. Reddy's, 5 mg/mL, 50 mL vial, 1 count, NDC 43598-0142-11
- Nelarabine injection, Dr. Reddy's, 5 mg/mL, 50 mL vial, 6 count, NDC 43598-0142-06
- Nelarabine injection, Meitheal Pharmaceuticals, 5 mg/mL, 50 mL vial, 1 count, NDC 71288-0165-54
- Nelarabine injection, Novadoz, 5 mg/mL, 50 mL vial, 1 count, NDC 72205-0154-01
- Nelarabine injection, Novadoz, 5 mg/mL, 50 mL vial, 6 count, NDC 72205-0154-04
- Nelarabine injection, Shorla Oncology, 5 mg/mL, 50 mL vial, 1 count, NDC 81927-0111-01
- Nelarabine injection, Shorla Oncology, 5 mg/mL, 50 mL vial, 6 count, NDC 81927-0111-06
- Nelarabine injection, X-Gen, 5 mg/mL, 50 mL vial, 1 count, NDC 39822-0650-01
- Nelarabine injection, X-Gen, 5 mg/mL, 50 mL vial, 6 count, NDC 39822-0650-06

Estimated Resupply Dates

- Sagent has nelarabine 5 mg/mL 50 mL vials in 1 count and 6 count on back order and the company estimates a release date of April 2025.
- Zydus has nelarabine 5 mg/mL 50 mL vials on back order and the company estimates a release date in late-April 2025.

Updated

Updated April 3, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 17, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.